This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Latexin sensitizes leukemogenic cells to gamma-irradiation-induced cell-cycle arrest and cell death through Rps3 pathway
Cell Death & Disease Open Access 23 October 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al., UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group: NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239.
Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.
Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT . Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477–484.
Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006; 20: 1159–1161.
Pettitt AR, Matutes E, Oscier D . Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441–1445.
Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D . The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90: 1435–1436.
Stilgenbauer S, Döhner H . Alemtuzumab-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–453.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute—Working Group (NCI-WG) 1996 guidelines. Blood 2008; published online 23 January 2008, doi:10.1182/blood-2007-06-093906.
Acknowledgements
This work was supported by ‘Deutsche José Carreras Leukämie-Stiftung (R06/28v)’ and the ‘Else Kröner-Fresenius-Stiftung (P20/07//A11/07)’.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Zenz, T., Häbe, S., Denzel, T. et al. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. Leukemia 22, 2257–2258 (2008). https://doi.org/10.1038/leu.2008.114
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.114
This article is cited by
-
Latexin sensitizes leukemogenic cells to gamma-irradiation-induced cell-cycle arrest and cell death through Rps3 pathway
Cell Death & Disease (2014)
-
What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
Current Hematologic Malignancy Reports (2013)
-
From pathogenesis to treatment of chronic lymphocytic leukaemia
Nature Reviews Cancer (2010)